Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Reports Stock Sale
SEC Form 4
Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the sale of 2,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 1, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, sold 2,000 shares of the company's common stock.
- The sale was executed at a price of $68.63 per share.
- This transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted on November 9, 2023.
- Following the transaction, Parsey directly owns 96,380 shares of Gilead Sciences' common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan, with no indication of positive or negative implications for the company.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-11-09 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-07-01 | Date of stock sale transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.